Scientists at The University of Manchester have developed the first non-antibiotic drug to successfully treat tuberculosis in animals.
The team hope the compound –developed after 10 years of painstaking research will be trialled on humans within three to four years.
The drug- which works by targeting Mycobacterium tuberculosis’ defences rather than the bacteria itself – can also take out its increasingly commonly antibiotic resistant strains.
The research funded by the Medical Research Council – is published today in the Journal of Medicinal Chemistry.
Although a vaccine for TB was developed 100 years ago, one in three people across the world are thought to be infected with the infectious disease.
About 1.7 million die from the bug each year worldwide and 7.3 million people were diagnosed and treated in 2018, up from the 6.3 million in 2016.
It is most common in Africa, India and China, but on the rise in the UK with London often described as the TB capital of Europe.
Patients are forced to take a cocktail of strong antibiotics over 6 to 8 months, often enduring unpleasant side effects with a 20% risk that the disease will return.
But now The University of Manchester team’s discovery has been proven effective in guinea pigs at Rutgers University in the United States.
The animals with acute and chronic TB infection were treated with the compound, which was discovered after investigating dozens of other derivatives and compounds thought to have similar properties.
Professor Lydia Tabernero is the project leader. She said: “The fact that the animal studies showed our compound, which doesn’t kill the bacteria directly, resulted in a significant reduction in the bacterial burden is remarkable.
“For more than 60 years, the only weapon doctors have been able to use against TB is antibiotics. But resistance is becoming an increasingly worrying problem and the prolonged treatment is difficult and distressing for patients.
“And with current treatments, there’s no guarantee the disease will be eliminated: antibiotics do not clear the infection and the risk of being infected with drug-resistant bacteria is very high.
“But by disabling this clandestine bacteria’s defences we’re thrilled to find a way that enhances the chances of the body’s immune system to do its job, and thus eliminate the pathogen.”
Mycobacterium Tuberculosis secretes molecules called Virulence Factors – the cell’s secret weapon -which block out the immune response to the infection, making it difficult to treat.
The team identified one Virulence Factor called MptpB as a suitable target, which when blocked allows white blood cells to kill Mycobacterium Tuberculosis in a more efficient way
Professor Tabernero added: “The great thing about MptpB is that there’s nothing similar in humans – so our compound which blocks it is not toxic to the human cells.
“Because the bacteria hasn’t been threatened directly, it is less likely to develop resistance against this new agent, and this will be a major advantage over current antibiotics, for which bacteria had already become resistant.
“TB is an amazingly difficult disease to treat so we feel this is a significant breakthrough.
”The next stage of our research is to optimise further the chemical compound, but we hope clinical trials are up to four years away.”
Learn more: Scientists develop new drug treatment for TB
The Latest on: Tuberculosis
via Google News
The Latest on: Tuberculosis
- Specific HIV and tuberculosis medications decrease risk of death in adults with drug-resistant TBon August 10, 2020 at 10:32 pm
After looking at the health records of over 10,000 patients with both HIV and multidrug resistant Tuberculosis (TB) in over 20 different countries, researchers at the Perelman School of Medicine at ...
- Tuberculosis vaccine may help protect against COVID-19: Israeli researchon August 10, 2020 at 12:09 pm
Israeli researchers have found that vaccinations against tuberculosis may provide additional protection against COVID-19, Ben Gurion University (BGU) in southern Israel said Monday.
- Tuberculosis vaccine research could benefit the elderly and diabeticson August 10, 2020 at 12:01 pm
A study of older mice with type 2 diabetes has yielded highly promising results for researchers investigating potential new vaccines for tuberculosis (TB).
- Research suggests greater access to specific HIV and tuberculosis medications is neededon August 10, 2020 at 6:09 am
A specific combination of HIV and TB treatments, difficult to obtain in certain parts of the world, decreased mortality risk for patients with HIV and multidrug-resistant TB.
- Tuberculosis Testing Market 2020 By Industry Size Estimation, Industry Share, Future Demand, Dynamics, Drivers, Research Methodology By 2024on August 10, 2020 at 4:59 am
Global "Tuberculosis Testing Market" report exhibits a pin-point breakdown of Industry dependent on type, applications, ...
- Prevalence of HIV infection and bacteriologically confirmed tuberculosis among individuals found at bars in Kampala slums, Ugandaon August 10, 2020 at 2:13 am
Individuals found at bars in slums have several risk factors for HIV and tuberculosis (TB). To determine the prevalence of HIV and TB among individuals found at bars in slums of Kampala, Uganda, we ...
- Tuberculosis Diagnostic Market Growth, Recent Trends by Regions, Type, Application and Geographical Analysis to 2026on August 7, 2020 at 5:05 am
Final Report will add the analysis of the impact of COVID-19 on this industry” The "Tuberculosis Diagnostic Market" ...
- World film premiere: Death of cell infected with tuberculosison August 6, 2020 at 9:13 am
Probably every fourth person harbors tuberculosis bacteria in their body, although only five to ten percent of the infected population actually get sick. People who contract the illness need to take ...
- NYT: Tuberculosis, HIV, Malaria are spreading...on August 5, 2020 at 4:36 pm
Tuberculosis, HIV, Malaria are spreading", a CBSN video on CBSNews.com. View more CBSN videos and watch CBSN, a live news stream featuring original CBS News reporting.
via Bing News